Diversion Control Division, US Department of Justice, Drug Enforcement Administration

Manufacturers Notice of Application - 2000

[Federal Register: March 6, 2000 (Volume 65, Number 44)] [Notices] [Page 11801] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr06mr00-69] 


Drug Enforcement Administration

Manufacturer of Controlled Substancies; Notice of Application 

Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 14, 2000, Chattem Chemicals, Inc., 3708 St. Elmo Avenue, Chattanooga, Tennessee 34709, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of amphetamine (1100), a basic class of controlled substance listed in Schedule II. 

The firm plans to bulk manufacture amphetamine for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration. 

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than May 5, 2000. 

Dated: February 25, 2000. 

John H. King, 
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. 

[FR Doc. 00-5257 Filed 3-3-00; 8:45 am] 


NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).

Emergency Disaster Relief
Search for Year Round Pharmaceutical Disposal Locations.
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility